{"id":"vka-based-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Warfarin-induced skin necrosis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Drug-drug interactions"}]},"_chembl":{"chemblId":"CHEMBL324631","moleculeType":"Small molecule","molecularWeight":"643.29"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Vitamin K antagonists (VKAs) such as warfarin work by inhibiting the vitamin K-dependent gamma-carboxylation of clotting factors II, VII, IX, and X in the liver, thereby reducing their procoagulant activity. This anticoagulant effect is used to prevent and treat thromboembolic disorders. VKA-based regimens typically involve dose titration to achieve a target International Normalized Ratio (INR) for the specific clinical indication.","oneSentence":"VKA-based regimens inhibit vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombus formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:41.078Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (DVT/PE) prevention and treatment"},{"name":"Mechanical heart valve thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT02943785","phase":"PHASE3","title":"Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-21","conditions":"Atrial Fibrillation","enrollment":1426},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-02-24","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT02942576","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-03-21","conditions":"Atrial Fibrillation","enrollment":632}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Warfarin","Phenprogamma","Phenprocoumon","Previscan","Fluindione"],"phase":"phase_3","status":"active","brandName":"VKA-Based Regimen","genericName":"VKA-Based Regimen","companyName":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","companyId":"daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VKA-based regimens inhibit vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombus formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}